Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

187.10USD
3:59pm EST
Change (% chg)

$-2.98 (-1.57%)
Prev Close
$190.08
Open
$191.44
Day's High
$191.92
Day's Low
$184.42
Volume
1,420,657
Avg. Vol
1,170,412
52-wk High
$210.18
52-wk Low
$163.31

Latest Key Developments (Source: Significant Developments)

Amgen announces 10 percent increase in 2019 first quarter dividend
Friday, 7 Dec 2018 04:00pm EST 

Dec 7 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 10 PERCENT INCREASE IN 2019 FIRST QUARTER DIVIDEND.INCREASES QUARTERLY DIVIDEND BY 10 PERCENT.SETS QUARTERLY DIVIDEND OF $1.45PER SHARE.  Full Article

Amgen Receives CHMP Positive Opinion To Expand Use Of Blincyto
Friday, 16 Nov 2018 09:00am EST 

Nov 16 (Reuters) - Amgen Inc ::AMGEN RECEIVES CHMP POSITIVE OPINION TO EXPAND USE OF BLINCYTO® (BLINATUMOMAB) IN PATIENTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA.AMGEN INC - APPLICATION BASED ON DATA FROM PHASE 2 BLAST STUDY.  Full Article

Temasek Holdings (Private) Ltd Dissolves Share Stake In Walt Disney, Amgen and Biogen
Wednesday, 14 Nov 2018 06:30am EST 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN WALT DISNEY CO - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN AMGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN BIOGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALEXION PHARMACEUTICALS INC BY 18.5 PERCENT TO 1.2 MILLION SHARES.TEMASEK HOLDINGS (PRIVATE) LTD REPORTS SHARE STAKE OF 4.5 MILLION SHARES IN FARFETCH LTD.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
Monday, 5 Nov 2018 09:00am EST 

Nov 5 (Reuters) - Amgen Inc ::PROVENTION BIO INC - AMGEN WILL INVEST $20 MILLION IN PROVENTION EQUITY.PROVENTION BIO INC - AMGEN AND PROVENTION BIO ANNOUNCE CO-DEVELOPMENT COLLABORATION IN CELIAC DISEASE.PROVENTION BIO INC - AMGEN WILL BE RESPONSIBLE FOR CLINICAL TRIAL SUPPLY AND MANUFACTURING.PROVENTION BIO INC - WILL CONDUCT AND FUND A PHASE 2B TRIAL IN NRCD AND LEAD NEXT PHASE OF DEVELOPMENT AND REGULATORY ACTIVITIES FOR PROGRAM.PROVENTION BIO INC - UPON COMPLETION OF PHASE 2B TRIAL, PROVENTION WILL BE ELIGIBLE TO RECEIVE A $150 MILLION MILESTONE PAYMENT.PROVENTION - UPON COMPLETION TRIAL, WILL BE ALSO BE ELIGIBLE TO RECEIVE ADDITIONAL MILESTONE PAYMENTS IF AMGEN CONTINUES AMG 714 DEVELOPMENT.  Full Article

Amgen Announces Top-Line Results From Phase 3 Study Of Abp 710, Biosimilar Candidate To Infliximab
Wednesday, 27 Jun 2018 09:00am EDT 

June 27 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 710, BIOSIMILAR CANDIDATE TO INFLIXIMAB.AMGEN INC - RESULTS CONFIRM NON-INFERIORITY COMPARED TO INFLIXIMAB BUT COULD NOT RULE OUT SUPERIORITY BASED ON ITS PRIMARY EFFICACY ENDPOINT.AMGEN - RESULTS FROM STUDY CONFIRM NON-INFERIORITY COMPARED TO INFLIXIMAB BUT COULD NOT RULE OUT SUPERIORITY BASED ON ITS PRIMARY EFFICACY ENDPOINT.AMGEN - PRIMARY ENDPOINT OF ACR20 HAD PRESPECIFIED EQUIVALENCE MARGIN OF +/- 15 PERCENT , AND OBSERVED UPPER END OF CONFIDENCE INTERVAL WAS 15.96 PERCENT.AMGEN INC - ACR50 AND ACR70 TRENDED IN SAME DIRECTION AS ACR20.AMGEN INC - OVERALL, SAFETY PROFILE AND IMMUNOGENICITY WERE COMPARABLE BETWEEN ABP 710 AND INFLIXIMAB.  Full Article

Health Canada Approves Amgen's Repatha To Reduce Risk Of Cardiovascular Events
Tuesday, 19 Jun 2018 08:00am EDT 

June 19 (Reuters) - Amgen Inc ::HEALTH CANADA APPROVES AMGEN'S REPATHA® (EVOLOCUMAB) TO REDUCE RISK OF CARDIOVASCULAR EVENTS IN ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE.  Full Article

FDA Approves Addition Of Survival Data From Phase 3 Aspire Trial To Kyprolis Label
Monday, 11 Jun 2018 09:00am EDT 

June 11 (Reuters) - Amgen Inc ::FDA APPROVES ADDITION OF POSITIVE OVERALL SURVIVAL DATA FROM PHASE 3 ASPIRE TRIAL TO KYPROLIS® (CARFILZOMIB) LABEL.AMGEN INC - SAFETY DATA WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF KYPROLIS.AMGEN INC - KYPROLIS, LENALIDOMIDE AND DEXAMETHASONE EXTENDED MEDIAN OVERALL SURVIVAL IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS TO 48 MONTHS.  Full Article

FDA Approves Prolia For Glucocorticoid-Induced Osteoporosis
Monday, 21 May 2018 04:00pm EDT 

May 21 (Reuters) - Amgen Inc ::FDA APPROVES PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS.FDA APPROVES PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS.AMGEN INC - SAFETY RESULTS WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF PROLIA.AMGEN INC - APPROVAL OF PROLIA FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS IS BASED ON DATA FROM A PHASE 3 STUDY.  Full Article

Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention
Thursday, 17 May 2018 07:11pm EDT 

May 17 (Reuters) - Novartis Ag ::NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION.EMA MARKETING AUTHORIZATION APPLICATION FOR AIMOVIG IS UNDER REVIEW. NOVARTIS EXPECTS APPROVAL IN EU IN COMING MONTHS.  Full Article

Amgen Says FDA Approves Aimovig, A Treatment For Migraine Prevention
Thursday, 17 May 2018 07:04pm EDT 

May 17 (Reuters) - Amgen Inc ::FDA APPROVES AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION.AIMOVIG IS EXPECTED TO BE AVAILABLE TO PATIENTS WITHIN ONE WEEK.  Full Article

Photo

Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.